|Bid||20.55 x 600|
|Ask||21.25 x 300|
|Day's range||22.75 - 23.75|
|52-week range||3.65 - 23.75|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2018 - 7 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.80|
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
On another record day for Wall Street, Dominion Energy moved to make an acquisition and Sangamo announced a new collaboration with Pfizer.
Sangamo Therapeutics Inc. shares surged 3.4% in premarket trade on Wednesday after news of the company's $12 million collaboration with Pfizer Inc. on a gene therapy for two neurodegenerative disorders, ...
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.
Sangamo Therapeutics, Inc. (SGMO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
The Richmond, California-based company said it had a loss of 15 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...